盐酸纳洛酮(Naloxone hydrochloride) - 药物靶点：μ opioid receptor_在研适应症：急性淋巴细胞白血病，阿片类药物过量，阿片滥用_专利_临床

概要

基本信息

简介纳洛酮是一种小分子药物， μ 阿片受体的拮抗剂。该药物通过阻断受体位点、逆转阿片类药物对中枢神经系统的影响并恢复正常呼吸来发挥作用。纳洛酮最初由 Endo Pharmaceuticals 开发，于 1971 年首次获准使用。

药物类型

小分子化药

别名

Naloxone、Naloxone hydrochloride (JP17/USP)、Naloxone hydrochloride dihydrate

+ [46]

靶点

μ opioid receptor

作用方式

拮抗剂

作用机制

μ opioid receptor拮抗剂(μ-阿片受体拮抗剂)

治疗领域

肿瘤免疫系统疾病血液及淋巴系统疾病+ [1]

在研适应症

急性淋巴细胞白血病阿片类药物过量阿片滥用

非在研适应症-

原研机构

Endo Pharmaceuticals, Inc.

Bexson Biomedical, Inc.

在研机构

Hikma Pharmaceuticals LLC

Nasus Pharma Ltd.

Crossject SA

+ [11]

非在研机构

Emergent Operations Ireland Ltd

Kaleo, Inc.

Scienture LLC

+ [1]

权益机构

Summit Biosciences, Inc.ZMI Pharma, Inc.

Harm Reduction Therapeutics, Inc.

+ [10]

最高研发阶段批准上市

首次获批日期

美国 (1971-04-13),

阿片类药物过量

最高研发阶段(中国)批准上市

特殊审评优先审评 (美国)、快速通道 (美国)、孤儿药 (欧盟)

登录后查看时间轴

结构/序列

分子式C19H22ClNO4

InChIKeyRGPDIGOSVORSAK-STHHAXOLSA-N

CAS号357-08-4

关联

224

项与盐酸纳洛酮相关的临床试验

NCT06251609

/ Not yet recruiting临床2期IIT

Naloxone for Opioid Associated Out of Hospital Cardiac Arrest

The investigator's long-term goal is to conduct Naloxone for Opioid Associated out of Hospital Cardiac Arrest (NOPACA), a randomized, double blind, controlled trial to determine the efficacy of naloxone vs. placebo in Opioid Associated out of Hospital Cardiac Arrest. The investigative team plan to randomize patients in OHCA to early naloxone administration vs. placebo after initial resuscitation and measure ROSC and survival. Challenges to designing NOPACA include uncertainty regarding: 1) the available pool of participants and number of EMS agencies needed to meet enrollment targets; 2) acceptability among patients, EMS and Emergency Medicine provider stakeholders, and 3) estimates of the study outcomes needed for sample size estimates. Toward obtaining the necessary information to design NOPACA, the investigators propose a pilot RCT of participants at high risk for OA-OHCA to verify a reasonable recruitment rate; treatment fidelity and acceptability; and adequate retention and measurement of outcomes at follow up. The investigators propose incorporating hypothesis testing of the feasibility outcomes to determine progression to a definitive trial.

开始日期2026-11-01

申办/合作机构

The University of California, San Francisco

NCT07079241

/ Not yet recruitingN/A

REgion Skåne Preventing Overdose Through Naloxone Distribution With Emergency Runners: a Feasibility Study for a Model to Save Lives Through a Volunteer First Responder Service Providing Antidote Treatment in Opioid Overdose

Opioids are responsible for the greatest drug-related global health burden. Prevention and treatment programs for people with opioid use disorder are widely implemented, but further actions are required to reduce the mortality and morbidity caused by opioid use and dependence. We suggest a novel and unique approach with a volunteer first responder system for suspected opioid overdoses, integrated with national emergency call services. The idea derives from the success of volunteer first responder systems for out-of-hospital cardiac arrests. Several reports exist globally with results of increased survival rates, less complications and a beneficial time-gain to start of cardiopulmonary resuscitation before emergency services (like ambulance and fire fighters) arrival.
Our model aims to investigate feasibility, acceptability and safety of a smartphone-based volunteer first responder system for suspected opioid overdoses. The volunteer responders will be equipped with an emergency kit including two doses of the opioid antidote naloxone, which can reverse life-threatening respiratory arrest caused by intoxication of opioids. The responders will, prior to registration, accomplish an in-depth overdose and naloxone education, as well as a first aid course aligned with current European and Swedish resuscitation guidelines. The results will be collected through questionnaires to the responder participants, technical data from the responder application, and dispatcher, pre-medical/paramedical and hospital records among others. Both quantitative and qualitative methods will be used. The major question is if the model is feasible in alerting lay persons with naloxone to suspected overdose situations and successfully administer naloxone prior to emergency service arrival. Furthermore, experiences of safety during alerts among volunteer first responders and overdose victims will also be studied.
Our model is unique in its integration with emergency medical dispatch service along with overdose and first aid education prior to participant registration. The respiratory arrest of opioids is an acute life-threatening condition, which - in similarity to cardiac arrests - need emergent actions for survival. A reduced time to naloxone administration through volunteer first responders prior to ambulance arrival could save lives.

开始日期2025-09-01

申办/合作机构

Region Skåne Holding AB

[+3]

NCT04650841

/ Not yet recruiting早期临床1期IIT

The Role of the Opioid System in Placebo Effects on Pain and Social Rejection

The current study probes the involvement of the opioid system in placebo effects on social pain, using the opioid antagonist naloxone. 60 participants who recently experienced an unwanted breakup will experience rejection-related stimuli and receive painful heat and pressure stimuli during fMRI scanning. Participants will be randomized to receive either a naloxone or saline nasal spray, and be informed that the spray is either saline, or an effective pain and negative emotion reducing agent.

开始日期2025-09-01

申办/合作机构

Trustees of Dartmouth College

100 项与盐酸纳洛酮相关的临床结果

登录后查看更多信息

100 项与盐酸纳洛酮相关的转化医学

登录后查看更多信息

100 项与盐酸纳洛酮相关的专利（医药）

登录后查看更多信息

27,719

项与盐酸纳洛酮相关的文献（医药）

2026-02-01·JOURNAL OF CRITICAL CARE

Evaluation of opioid requirements in mechanically ventilated patients taking buprenorphine/naloxone prior to admission

Article

作者: Kamp, Ashley ; Erkanli, Alaattin ; Cox, Christopher E ; Yang, Lexie Zidanyue ; Kuhrt, Michelle ; Kram, Bridgette ; Mertz, Sean ; O'Connell, Molly

BACKGROUND:

With limited data quantifying opioid requirements based on substance use history, including buprenorphine/naloxone use, optimal pain management for mechanically ventilated patients remains unknown.

OBJECTIVE:

To compare opioid requirements in mechanically ventilated adults admitted to the intensive care unit (ICU) taking buprenorphine/naloxone prior to admission compared to those who do not.

METHODS:

This multicenter, retrospective study included adults admitted to a medical ICU and mechanically ventilated for at least 12 h. The primary endpoint was mean hourly opioid rate (fentanyl equivalents [FE], μg FE/h) from intubation until extubation or up to 72 h. Secondary endpoints included sedative requirements and time with pain and depth of sedation scores within goal. To adjust for confounders, a negative binomial model was performed.

RESULTS:

Of 176 patients, 47 took buprenorphine/naloxone, 69 were opioid-naïve, and 60 were opioid-tolerant. There was no difference in mean hourly opioid rate between buprenorphine/naloxone (40.8 ± 37.1 μg FE/h) and opioid-naïve (31.7 ± 32.5 μg FE/h; p = 0.17) and opioid-tolerant patients (51 ± 46 μg FE/h; p = 0.22). Multivariable regression demonstrated similar hourly rates in buprenorphine/naloxone and opioid-naïve patients, but opioid-tolerant patients had 50 % higher rates (estimated rate ratio 1.5, 95 % CI [1.01, 2.23]). Time spent with pain scores at goal was similar. Time spent with sedation scores at goal was similar between buprenorphine/naloxone and opioid-naïve patients, but was lower than opioid-tolerant patients.

CONCLUSION:

Patients taking buprenorphine/naloxone prior to admission who are mechanically ventilated for at least 12 h may have opioid requirements similar to opioid-naïve patients and lower than opioid-tolerant patients.

2026-01-01·JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION

The minivisit method: Adapting opioid-related educational outreach for community pharmacies

Article

作者: Walsh, Sharon L ; Stinson, Laura K ; Roberts, Monica F ; Freeman, Patricia R ; Matson, Adrienne

Community pharmacists are well-positioned to contribute to public health initiatives related to prescription opioid safety and naloxone access, but many barriers, including gaps in knowledge and confidence, prevent them from fully engaging with their patients and communities on these topics. The Kentucky site of the HEALing (Helping to End Addiction Long-term Initiative®) Communities Study sought to involve community pharmacists in the effort to prevent opioid-related overdose deaths. Throughout the study, strategies to provide in-person educational outreach to community pharmacists were developed, implemented, and redesigned, resulting in a new format: the minivisit method. Minivisits are based on the principles of academic detailing but aim to more efficiently meet the needs of busy community pharmacists. Implemented by pharmacists for pharmacists, minivisits deliver key messages in brief, unscheduled visits to all community pharmacies in an identified geographic area. Paired with on-going support, high-quality printed materials, and in-depth continuing education activities, minivisits offer a promising alternative to traditional education formats. The minivisit method can be adapted to the goals, budget, and educational needs of a given program. This commentary details the trial-and-error process by which minivisits were developed and implemented and the key components of the minivisit method. The aim of this commentary is to inspire and inform future efforts to educate community pharmacists and expand practice to improve public health.

2026-01-01·PHYSIOLOGY & BEHAVIOR

Analysis of the nonclinical safety and antinociceptive potential of amentoflavone (AMT) on corneal pain in adult zebrafish (Danio rerio)

Article

作者: de Sousa, Daniela Braga ; de Azevedo, Djane Ventura ; Campos, Adriana Rolim ; Sobrinho, Francisco Bastos Cavalcante ; de Morais, Selene Maia ; Ishiki, Hamilton Mitsugu ; Bezerra, Franciglauber Silva ; Sabóia, Lia Gomes Crisóstomo ; Batista, Francisco Lucas Alves ; Frota, Lucas Soares ; Nascimento, Gabriela Alves do ; Santos, Sacha Aubrey Alves Rodrigues ; Magalhães, Francisco Ernani Alves

Corneal pain affects the outer layer of the eye and can result from injuries, infections, autoimmune diseases, or dry eye syndrome. Amentoflavone (AMT), a natural biflavonoid used in traditional Chinese medicine, is known for its anti-inflammatory and neuroprotective properties. This study investigated the effects of AMT on the inhibition of corneal pain in adult zebrafish. Acute nociception was induced using formalin (cutaneous model) and hypertonic saline solution (corneal model). In a separate set of experiments, animals were pre-treated with naloxone, camphor, ruthenium red, capsazepine, l-NAME, methylene blue, ketamine, or amiloride to explore the mechanisms underlying AMT's antinociceptive effects. The results demonstrated that AMT exhibits corneal analgesic activity comparable to morphine, without causing sedation or motor impairment in zebrafish. AMT modulated antinociceptive responses through the TRPV1, ASIC, opioid, and nitrergic systems. In the in silico analysis, AMT showed lower binding energies compared to the antagonists naloxone and l-NAME, suggesting greater stability and potential efficacy. These findings support the potential of AMT as a candidate for the development of new treatments for corneal pain.

655

项与盐酸纳洛酮相关的新闻（医药）

2025-11-14

·EINPresswire

Nove Device Expands Access to Lifesaving Naloxone Nasal Spray Carry Case

Nove Device creates discreet, everyday-carry kits to hold emergency naloxone nasal sprays, empowering users to respond quickly and without stigma. SAN FRANCISCO, CA, UNITED STATES, November 14, 2025 / EINPresswire.com / -- Nove Device continues to redefine public health preparedness with its innovative single dose nasal spray carry case for life saving medications such as Narcan ® (naloxone HCl), Kloxxado ® (naloxone HCl), Tosymra ® (sumatriptan), Imitrex ® (sumatriptan), Neffy ® (epinephrine nasal spray), or Zavzpret ® (zavegepant). The company is dedicated to providing people and organizations with life-saving equipment in times of need. Safety and Accessibility The company builds its naloxone nasal spray carry cases with safety and reliability in mind. Designed for first responders, healthcare professionals, and individuals in mind, the product gives quick and discreet storage of naloxone, ensuring it’s always within reach when seconds matter most. Combining innovation with compassion, the company provides durable, user-friendly designs that suit both active lifestyles and professional use. Their commitment to advancing life-saving technologies is evident through their continuous product enhancements and dedication to quality. Innovating Life-Saving Solutions Naloxone nasal spray carry solutions instill confidence in communities by promoting readiness, safety, and peace of mind. Each device reflects its passion for emergency response accessibility. Trusted by Leading Organizations Trusted by leading organizations, Nove Device is a reliable source that supplies durable, user-friendly emergency kits to communities through naloxone distribution and public health programs. Collaborations with healthcare providers, prevention programs, and first responders help to make naloxone keychain kits more accessible, empowering communities to respond swiftly in times of crisis. Leading health organizations across the U.S. trust Nove Device's "Emergency Nasal Spray Carry Case + Keychain" for its reliability and quick-access design. About Nove Device: Nove Device creates discreet, everyday-carry kits to hold emergency naloxone nasal sprays, empowering users to respond quickly and without stigma. For more information or to explore their full range of innovative products, contact their office or visit their website. Company name: Nove Device Address: 1917 Ellis Street Unit 3 State: California City: San Francisco Zip Code: 94115 Phone number: +1 317-445-3130 Email Address: contact@novedevice.com Nove Device Nove Device +1 317-445-3130 email us here Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

2025-11-14

·EINPresswire

Nove Device Introduces Innovative Naloxone Nasal Spray Carry Case for Emergency Preparedness

This kit is designed to educate individuals and communities on recognizing and responding to an overdose effectively. SAN FRANCISCO, CA, UNITED STATES, November 14, 2025 / EINPresswire.com / -- Nove Device has announced the launch of its innovative naloxone nasal spray carry case for emergency use. Committed to improving public safety and accessibility, the company continues to develop smart, reliable solutions designed to make life-saving tools more accessible during critical moments. Design for Saving Life The naloxone nasal spray carry emergency case is built with durability, portability, and discretion in mind. It ensures that users can keep their life saving medication, secure, and within easy reach at all times, including Narcan ® (naloxone HCl), Kloxxado ® (naloxone HCl), Tosymra ® (sumatriptan), Imitrex ® (sumatriptan), Neffy ® (epinephrine nasal spray), or Zavzpret ® (zavegepant. Designed for first responders, healthcare professionals, and everyday individuals, this carry case allows users to respond effectively in overdose and other life threatening emergencies. They specialize in practical design, and public health distribution, reflecting their ongoing commitment to community safety and innovation. Expanding Safety Solutions Beyond its functional advantages, the naloxone nasal spray carry case stands out for its modern, compact design that supports an active lifestyle. They prioritize quality materials, convenience, and protective features that offer peace of mind when every second counts. The company continues to expand its product line to meet the growing demand for health and safety products, enabling the public to be prepared wherever they go. Educational and Practical Design This kit is designed to educate individuals and communities on recognizing and responding to an overdose effectively. Each kit includes clear, easy-to-follow information and tools needed to act quickly—ideal for naloxone distribution programs or personal preparedness. About Nove Device: Nove Device designs innovative, portable naloxone carry cases that enhance emergency preparedness, promote overdose awareness, and empower communities to save lives safely and effectively. For more information or to learn more about their life-saving innovations, contact their office or visit their website. Company name: Nove Device Address: 1917 Ellis Street Unit 3 State: California City: San Francisco Zip Code: 94115 Phone number: +1 317-445-3130 Email address: contact@novedevice.com Nove Device Nove Device +1 317-445-3130 email us here Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

2025-11-14

·今日头条

苑东生物创新药和高端药里明显被错杀的品种，多个产品市占率领先，深入布局精麻特药公司已上市麻醉镇痛及相关领域产品共18个，其中新产品盐酸纳布啡注射液、酒石酸布托啡诺注射液均为精二类药品，盐酸纳美芬注射液已获美国FDA批准上市。根据米内网最新数据，麻醉镇痛领域盐酸纳美芬注射液、布洛芬注射液、盐酸纳洛

苑东生物创新药和高端药里明显被错杀的品种，多个产品市占率领先，深入布局精麻特药公司已上市麻醉镇痛及相关领域产品共18个，其中新产品盐酸纳布啡注射液、酒石酸布托啡诺注射液均为精二类药品，盐酸纳美芬注射液已获美国FDA批准上市。根据米内网最新数据，麻醉镇痛领域盐酸纳美芬注射液、布洛芬注射液、盐酸纳洛酮注射液等多个产品市占率领先。在研麻醉镇痛项目超20个，其中10余个为国家精麻管制药品。氨酚羟考酮缓释片和硫酸吗啡盐酸纳曲酮缓释胶囊均已申报生产，目前正在审评中。EP-9001A单抗注射液已完成Ib期临床研究。研发投入持续增长，重点推进创新药管线公司继续保持高比例研发投入，2025年上半年研发投入1.33亿元，同比增长8.74%，占营收20.25%，同比上升1.98个百分点。其中创新药研发投入约0.45亿元，占总体研发投入比例为33.83%。2025年6月，公司对超阳药业股权投资比例提升至30.68%。超阳药业在靶向蛋白降解领域构建了5条管线，其中新型口服CRBN基础的分子胶降解剂HP-001正在开展一期临床试验。此外，公司首款ADC创新药YLSH003已于2025年7月完成了IND申报并被受理。增持超阳加速研发，新型口服CRBN分子胶进击BIC超阳HP-001预计2025年内读出1a数据，2026H1读出1b临床数据。HP-001ORR数据积极，安全性良好，有望进击IKZF1/3分子胶领域的BIC。HP002是新一代具备透脑能力、靶向BTK的PROTAC分子，在临床前研究中对多种BTK突变体表现出强大的抗增殖活性，预计2025Q4申报中国IND。公司持有超阳股权比例增至30.6818%的事宜已于2025年7月完成受让参股公司部分股权交易款项支付，后续有望进一步增持，超阳的创新平台价值有望在公司体内持续体现。

100 项与盐酸纳洛酮相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01340	盐酸纳洛酮	A06AH04 V03AB15	DB01183

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
急性淋巴细胞白血病	加拿大	Hikma Pharmaceuticals LLC	2025-02-01
阿片类药物过量	美国	Emergent Devices, Inc.	1971-04-13

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
阿片滥用	临床前	美国	Consegna Pharma, Inc.	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03608163 (CTgov)	临床4期	1型糖尿病 \| 低血糖 \| 单纯自主神经功能衰竭 ... 更多	4	Naloxone (Naloxone)	範簾獵遞獵網構艱製衊(夢網簾膚淵鬱窪廠壓範) = 獵製鏇範積襯憲遞鏇鹽築獵遞壓願選淵憲廠膚 (齋襯鑰夢遞簾觸構憲壓, 134) 更多	-	2025-09-11
				Placebo (for Naloxone) (Placebo (for Naloxone))	範簾獵遞獵網構艱製衊(夢網簾膚淵鬱窪廠壓範) = 醖壓鬱廠蓋齋構繭構網築獵遞壓願選淵憲廠膚 (齋襯鑰夢遞簾觸構憲壓, 195) 更多
NCT03751111 (CTgov)	临床1/2期	瘙痒 \| 肛门瘙痒	126	Naloxone (Naloxone)	艱鬱繭構醖構淵觸範鹽(艱襯範顧壓鏇願膚願鹽) = 鏇糧醖獵齋餘窪構鹽築簾廠襯遞顧衊鏇廠積壓 (範鏇獵夢淵憲憲觸獵簾, 2.15) 更多	-	2025-04-20
				Placebo (Placebo)	艱鬱繭構醖構淵觸範鹽(艱襯範顧壓鏇願膚願鹽) = 醖鹹選夢艱選觸憲艱糧簾廠襯遞顧衊鏇廠積壓 (範鏇獵夢淵憲憲觸獵簾, 1.99) 更多
NCT04473950 (CTgov)	临床1期	阿片相关性障碍 \| 慢性疼痛	10	Placebo+Naloxone Hydrochloride (Pain Group)	築構繭願窪製築壓網艱(鏇醖鑰艱壓遞齋窪膚蓋) = 憲衊顧窪醖壓醖遞製鬱壓襯繭窪夢夢衊醖醖壓 (窪艱鬱鹽鏇衊觸齋膚選, 1.17) 更多	-	2025-03-26
				Placebo+Naloxone Hydrochloride (No Pain Group)	築構繭願窪製築壓網艱(鏇醖鑰艱壓遞齋窪膚蓋) = 簾膚構鏇願襯襯構淵醖壓襯繭窪夢夢衊醖醖壓 (窪艱鬱鹽鏇衊觸齋膚選, 0.92) 更多
NCT03176316 (FusionIleus, CTgov)	临床4期	肠阻塞	53	Naloxone	鑰鏇簾願獵壓遞鏇鹹願 = 糧憲構獵鏇鹹繭膚淵鏇鬱憲製廠範淵積繭顧構 (膚鹹壓窪積淵壓範獵願, 鑰簾膚衊衊製鏇鹽艱繭 ~ 網齋鹽遞遞鑰憲製醖鏇) 更多	-	2024-07-01
NCT03149770 (CTgov)	临床2期	低血糖 \| 1型糖尿病	30	Naloxone (Naloxone)	艱築觸膚醖壓繭衊艱製(積遞廠憲夢願憲艱網簾) = 鏇鏇齋願憲鹽壓獵蓋繭獵鹹膚簾艱觸繭齋鏇鹹 (選夢鏇構願網願夢觸襯, 12) 更多	-	2024-04-16
				placebo (Placebo)	艱築觸膚醖壓繭衊艱製(積遞廠憲夢願憲艱網簾) = 鏇選餘廠膚齋構積鹹獵獵鹹膚簾艱觸繭齋鏇鹹 (選夢鏇構願網願夢觸襯, 13) 更多
NCT04764630 (Pubmed \| JAMA Netw Open)	临床1期	阿片类药物过量	21	1 dose at 0, 2.5, 5, and 7.5 minutes	範壓蓋蓋選遞夢糧醖餘(淵衊選鑰願憲窪鏇襯範) = 遞廠襯襯獵鏇鏇簾鏇觸壓襯膚齋鹽範顧積衊遞 (積範鹹蓋鑰憲艱醖鑰構 )	-	2024-01-23
				2 doses at 0 and 2.5 minutes	範壓蓋蓋選遞夢糧醖餘(淵衊選鑰願憲窪鏇襯範) = 鑰窪願齋網衊簾簾製簾壓襯膚齋鹽範顧積衊遞 (積範鹹蓋鑰憲艱醖鑰構 )
NCT03570099 (Pubmed \| BMJ Open)	N/A	阿片类药物过量	-	Take-home naloxone distribution	簾齋糧製衊繭構觸觸選(鬱糧壓鏇壓齋糧艱餘製) = 糧獵艱艱壓蓋顧鏇膚餘衊鹽餘糧選觸窪憲糧鹽 (窪餘築艱鹹選壓網獵襯 )	-	2024-01-01
				intranasal naloxone (Control period (2013-2017))	簾齋糧製衊繭構觸觸選(鬱糧壓鏇壓齋糧艱餘製) = 衊鑰淵衊範淵廠製壓襯衊鹽餘糧選觸窪憲糧鹽 (窪餘築艱鹹選壓網獵襯 )
NCT02700048 (CTgov)	临床1/2期	1型糖尿病 \| 低血糖 \| 意识丧失	11	Intra-nasal saline (Placebo)	製鹹壓襯繭構鬱鏇鹹顧(顧製醖鏇遞顧廠淵廠淵) = 觸蓋襯網襯襯衊齋積繭鏇鹹顧淵構淵壓觸壓餘 (積窪獵蓋製鬱醖醖顧製, 製窪蓋鹹構鏇齋衊範齋 ~ 網膚鑰醖構鬱網鹽鏇糧) 更多	-	2023-03-27
				intra-nasal naloxone (Treatment With Intra-nasal Naloxone)	製鹹壓襯繭構鬱鏇鹹顧(顧製醖鏇遞顧廠淵廠淵) = 繭鹽選構繭範糧憲齋憲鏇鹹顧淵構淵壓觸壓餘 (積窪獵蓋製鬱醖醖顧製, 壓襯醖醖醖蓋壓壓鑰壓 ~ 願窪蓋鹹網壓鑰蓋鑰壓) 更多
NCT04713709 (Corporate Publications) 人工标引	临床1期	阿片类药物过量	56	FMXIN001	範鹽遞糧顧獵簾齋艱壓(餘獵蓋範壓網廠憲醖憲) = 夢願壓夢艱廠壓鏇窪壓襯鏇膚蓋範襯鹹鏇構製 (構製壓窪遞繭鏇齋製獵 ) 更多	相似	2022-07-28
				NARCAN	範鹽遞糧顧獵簾齋艱壓(餘獵蓋範壓網廠憲醖憲) = 壓襯鬱膚繭鹹構觸獵選襯鏇膚蓋範襯鹹鏇構製 (構製壓窪遞繭鏇齋製獵 ) 更多
NCT04764630 (CTgov)	临床1期	-	21	naloxone (A. Four Naloxone Nasal Spray Doses (1 Every 2.5 Min))	鏇憲積壓齋簾選衊醖壓(簾餘襯鏇襯鬱築壓壓簾) = 淵衊衊簾範襯鬱築膚構膚膚夢窪觸壓獵鹽淵範 (襯積夢網簾鏇夢鏇鹽壓, 70) 更多	-	2022-07-15
				naloxone (C. Two Naloxone Nasal Spray Doses (1 Every 2.5 Min))	鏇憲積壓齋簾選衊醖壓(簾餘襯鏇襯鬱築壓壓簾) = 蓋簾襯鏇蓋壓壓廠艱願膚膚夢窪觸壓獵鹽淵範 (襯積夢網簾鏇夢鏇鹽壓, 159) 更多